Ryvu Therapeutics S.A. (WSE:RVU)

Poland · Delayed Price · Currency is PLN

23.90

+0.35 (1.49%)

Apr 28, 2026, 5:00 PM CET

-22.40% (1Y)

Market Cap	552.57M
Revenue (ttm)	87.70M
Net Income (ttm)	-101.23M
Shares Out	23.12M
EPS (ttm)	-4.38
PE Ratio	n/a
Forward PE	8.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,476
Average Volume	35,043
Open	23.50
Previous Close	23.55
Day's Range	23.25 - 23.90
52-Week Range	20.50 - 36.00
Beta	0.59
RSI	49.07
Earnings Date	May 21, 2026

About Ryvu Therapeutics

Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company’s lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops Dapolsertib (SEL24/MEN1703), a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2007

Employees 228

Stock Exchange Warsaw Stock Exchange

Ticker Symbol RVU

Full Company Profile

Financial Performance

In 2025, Ryvu Therapeutics's revenue was 87.70 million, a decrease of -13.98% compared to the previous year's 101.96 million. Losses were -101.23 million, -9.16% less than in 2024.

Financial Statements

News

Ryvu Therapeutics Transcript: Study Update

RVU120 is being evaluated in four Phase II studies for hematologic malignancies, showing early signs of efficacy and a favorable safety profile, especially in genetically defined AML and MDS cohorts. Enrollment and operational progress are strong, with key data readouts expected in the first half of 2025.

1 year ago - Transcripts